Literature DB >> 9188468

Localization and suppression of a kinetic defect in cystic fibrosis transmembrane conductance regulator folding.

B H Qu1, E H Strickland, P J Thomas.   

Abstract

A growing body of evidence indicates that the most common cystic fibrosis-causing mutation, DeltaF508, alters the ability of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to fold and transit to the plasma membrane. Here we present evidence that the DeltaF508 mutation affects a step on the folding pathway prior to formation of the ATP binding site in the nucleotide binding domain (NBD). Notably, stabilization of the native state with 4 mM ATP does not alter the temperature-dependent folding yield of the mutant DeltaF508 NBD1 in vitro. In contrast, glycerol, which promotes DeltaF508-CFTR maturation in vivo, increases the folding yield of NBD1DeltaF and reduces the off pathway rate in vitro, although it does not significantly alter the free energy of stability. Likewise a second site mutation, R553M, which corrects the maturation defect in vivo, is a superfolder which counters the effects of DeltaF508 on the temperature-dependent folding yield in vitro, but does not significantly alter the free energy of stability. A disease-causing mutation, G551D, which does not alter the maturation of CFTR in vivo but rather its function as a chloride channel, and the S549R maturation mutation have no discernible effect on the folding of the domain. These results demonstrate that DeltaF508 is a kinetic folding mutation that affects a step early in the process, and that there is a significant energy barrier between the native state and the step affected by the mutation precluding the use of native state ligands to promote folding. The implications for protein folding in general are that the primary sequence may not necessarily simply define the most stable native structure, but rather a stable structure that is kinetically accessible.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188468     DOI: 10.1074/jbc.272.25.15739

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

Review 1.  Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.

Authors:  J R Riordan
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

2.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR.

Authors:  Andrei A Aleksandrov; Pradeep Kota; Liying Cui; Tim Jensen; Alexey E Alekseev; Santiago Reyes; Lihua He; Martina Gentzsch; Luba A Aleksandrov; Nikolay V Dokholyan; John R Riordan
Journal:  J Mol Biol       Date:  2012-03-08       Impact factor: 5.469

3.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity.

Authors:  Xuehong Liu; Nicolette O'Donnell; Allison Landstrom; William R Skach; David C Dawson
Journal:  Biochemistry       Date:  2012-06-15       Impact factor: 3.162

4.  Aptamer-Enabled Manipulation of the Hsp70 Chaperone System Suggests a Novel Strategy for Targeted Ubiquitination.

Authors:  Deepak Thirunavukarasu; Hua Shi
Journal:  Nucleic Acid Ther       Date:  2015-12-07       Impact factor: 5.486

5.  p97 functions as an auxiliary factor to facilitate TM domain extraction during CFTR ER-associated degradation.

Authors:  Eric J Carlson; David Pitonzo; William R Skach
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

6.  Positive co-operative activity and dimerization of the isolated ABC ATPase domain of HlyB from Escherichia coli.

Authors:  Houssain Benabdelhak; Lutz Schmitt; Carsten Horn; Kornelia Jumel; Mark A Blight; I Barry Holland
Journal:  Biochem J       Date:  2005-03-15       Impact factor: 3.857

7.  Activation mechanisms for the cystic fibrosis transmembrane conductance regulator protein involve direct binding of cAMP.

Authors:  Malcolm M C Pereira; Jody Parker; Fiona L L Stratford; Margaret McPherson; Robert L Dormer
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

8.  Mutations in the linker domain of NBD2 of SUR inhibit transduction but not nucleotide binding.

Authors:  Michinori Matsuo; Michael Dabrowski; Kazumitsu Ueda; Frances M Ashcroft
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

9.  Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator.

Authors:  Hal A Lewis; Sean G Buchanan; Stephen K Burley; Kris Conners; Mark Dickey; Michael Dorwart; Richard Fowler; Xia Gao; William B Guggino; Wayne A Hendrickson; John F Hunt; Margaret C Kearins; Don Lorimer; Peter C Maloney; Kai W Post; Kanagalaghatta R Rajashankar; Marc E Rutter; J Michael Sauder; Stephanie Shriver; Patrick H Thibodeau; Philip J Thomas; Marie Zhang; Xun Zhao; Spencer Emtage
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

Review 10.  Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability.

Authors:  P Andrew Chong; Pradeep Kota; Nikolay V Dokholyan; Julie D Forman-Kay
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.